vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and MID PENN BANCORP INC (MPB). Click either name above to swap in a different company.
MID PENN BANCORP INC is the larger business by last-quarter revenue ($62.0M vs $38.3M, roughly 1.6× ImmunityBio, Inc.). MID PENN BANCORP INC runs the higher net margin — 31.4% vs -161.8%, a 193.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 30.8%). MID PENN BANCORP INC produced more free cash flow last quarter ($71.8M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
IBRX vs MPB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $62.0M |
| Net Profit | $-61.9M | $19.4M |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | 43.6% |
| Net Margin | -161.8% | 31.4% |
| Revenue YoY | 407.0% | 30.8% |
| Net Profit YoY | -4.7% | 47.0% |
| EPS (diluted) | $-0.06 | $0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $62.0M | ||
| Q3 25 | $32.1M | $61.8M | ||
| Q2 25 | $26.4M | $54.3M | ||
| Q1 25 | $16.5M | $47.7M | ||
| Q4 24 | $7.6M | $47.4M | ||
| Q3 24 | $6.1M | $45.3M | ||
| Q2 24 | — | $44.1M | ||
| Q1 24 | — | $42.3M |
| Q4 25 | $-61.9M | $19.4M | ||
| Q3 25 | $-67.3M | $18.3M | ||
| Q2 25 | $-92.6M | $4.8M | ||
| Q1 25 | $-129.6M | $13.7M | ||
| Q4 24 | $-59.2M | $13.2M | ||
| Q3 24 | $-85.7M | $12.3M | ||
| Q2 24 | — | $11.8M | ||
| Q1 24 | — | $12.1M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | 43.6% | ||
| Q3 25 | -173.5% | 39.3% | ||
| Q2 25 | -269.8% | 7.9% | ||
| Q1 25 | -390.1% | 35.2% | ||
| Q4 24 | -919.0% | 34.1% | ||
| Q3 24 | -1314.3% | 32.8% | ||
| Q2 24 | — | 32.4% | ||
| Q1 24 | — | 34.8% |
| Q4 25 | -161.8% | 31.4% | ||
| Q3 25 | -209.8% | 29.6% | ||
| Q2 25 | -350.3% | 8.8% | ||
| Q1 25 | -784.9% | 28.8% | ||
| Q4 24 | -783.4% | 27.9% | ||
| Q3 24 | -1404.0% | 27.1% | ||
| Q2 24 | — | 26.7% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | $-0.06 | $0.83 | ||
| Q3 25 | $-0.07 | $0.79 | ||
| Q2 25 | $-0.10 | $0.22 | ||
| Q1 25 | $-0.15 | $0.71 | ||
| Q4 24 | $-0.08 | $0.72 | ||
| Q3 24 | $-0.14 | $0.74 | ||
| Q2 24 | — | $0.71 | ||
| Q1 24 | — | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $814.1M |
| Total Assets | $501.9M | $6.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | — | ||
| Q3 25 | $257.8M | — | ||
| Q2 25 | $153.7M | — | ||
| Q1 25 | $61.6M | — | ||
| Q4 24 | $149.8M | — | ||
| Q3 24 | $130.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-500.5M | $814.1M | ||
| Q3 25 | $-524.3M | $796.3M | ||
| Q2 25 | $-570.7M | $775.7M | ||
| Q1 25 | $-591.4M | $667.9M | ||
| Q4 24 | $-489.1M | $655.0M | ||
| Q3 24 | $-745.1M | $573.1M | ||
| Q2 24 | — | $559.7M | ||
| Q1 24 | — | $551.0M |
| Q4 25 | $501.9M | $6.1B | ||
| Q3 25 | $519.0M | $6.3B | ||
| Q2 25 | $402.1M | $6.4B | ||
| Q1 25 | $303.8M | $5.5B | ||
| Q4 24 | $382.9M | $5.5B | ||
| Q3 24 | $364.6M | $5.5B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | — | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $80.0M |
| Free Cash FlowOCF − Capex | $-71.3M | $71.8M |
| FCF MarginFCF / Revenue | -186.2% | 115.8% |
| Capex IntensityCapex / Revenue | 2.4% | 13.3% |
| Cash ConversionOCF / Net Profit | — | 4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $132.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $80.0M | ||
| Q3 25 | $-68.9M | $26.3M | ||
| Q2 25 | $-79.7M | $29.0M | ||
| Q1 25 | $-85.9M | $11.5M | ||
| Q4 24 | $-85.1M | $51.4M | ||
| Q3 24 | $-98.8M | $16.9M | ||
| Q2 24 | — | $18.0M | ||
| Q1 24 | — | $12.4M |
| Q4 25 | $-71.3M | $71.8M | ||
| Q3 25 | $-69.6M | $24.3M | ||
| Q2 25 | $-80.8M | $27.2M | ||
| Q1 25 | $-87.0M | $8.8M | ||
| Q4 24 | $-87.3M | $44.5M | ||
| Q3 24 | $-101.6M | $16.8M | ||
| Q2 24 | — | $17.7M | ||
| Q1 24 | — | $12.1M |
| Q4 25 | -186.2% | 115.8% | ||
| Q3 25 | -217.2% | 39.4% | ||
| Q2 25 | -305.9% | 50.1% | ||
| Q1 25 | -526.9% | 18.4% | ||
| Q4 24 | -1155.4% | 93.8% | ||
| Q3 24 | -1663.2% | 37.1% | ||
| Q2 24 | — | 40.2% | ||
| Q1 24 | — | 28.5% |
| Q4 25 | 2.4% | 13.3% | ||
| Q3 25 | 2.3% | 3.1% | ||
| Q2 25 | 4.1% | 3.2% | ||
| Q1 25 | 6.8% | 5.7% | ||
| Q4 24 | 28.0% | 14.6% | ||
| Q3 24 | 45.7% | 0.0% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | 4.12× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 6.08× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
